Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Trimmed by Fiera Capital Corp

Fiera Capital Corp decreased its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 5.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,037,248 shares of the biopharmaceutical company's stock after selling 175,313 shares during the period. Fiera Capital Corp owned about 1.02% of Amicus Therapeutics worth $28,611,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of FOLD. Wellington Management Group LLP lifted its position in shares of Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company's stock worth $255,936,000 after purchasing an additional 2,856,101 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Amicus Therapeutics by 1.2% during the third quarter. Geode Capital Management LLC now owns 6,599,871 shares of the biopharmaceutical company's stock worth $70,499,000 after acquiring an additional 80,926 shares during the period. Massachusetts Financial Services Co. MA increased its stake in shares of Amicus Therapeutics by 4.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,160,027 shares of the biopharmaceutical company's stock worth $33,749,000 after acquiring an additional 139,491 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Amicus Therapeutics by 10.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,667,271 shares of the biopharmaceutical company's stock worth $28,486,000 after acquiring an additional 242,672 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in shares of Amicus Therapeutics by 141.1% during the third quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company's stock worth $21,765,000 after acquiring an additional 1,192,489 shares during the period.

Amicus Therapeutics Stock Up 1.3 %

FOLD traded up $0.13 during trading hours on Monday, reaching $9.77. 1,944,625 shares of the stock traded hands, compared to its average volume of 2,020,068. The firm's fifty day simple moving average is $9.60 and its two-hundred day simple moving average is $10.43. The company has a market cap of $2.92 billion, a price-to-earnings ratio of -28.74, a PEG ratio of 1.69 and a beta of 0.61. Amicus Therapeutics, Inc. has a fifty-two week low of $8.78 and a fifty-two week high of $14.03. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42.

Insiders Place Their Bets

In other news, CEO Bradley L. Campbell sold 7,500 shares of the firm's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.02, for a total value of $75,150.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,884,273.08. This trade represents a 0.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Guggenheim upped their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Cantor Fitzgerald reissued an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. JPMorgan Chase & Co. upped their price objective on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an "overweight" rating in a research note on Tuesday, November 12th. Morgan Stanley reaffirmed an "equal weight" rating and set a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Finally, StockNews.com raised shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research note on Wednesday, February 12th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Amicus Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $16.88.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.